BIOCORP and NOVO NORDISK Sign Global Partnership Within Diabetes on Digital Health
- Biocorp and Novo Nordisk partner in the smart pen area, Biocorp
leveraging Mallya platform for the Novo Nordisk prefilled pen
- Mallya smart add-on device will attach directly to disposable
pre-filled FlexTouch® pens. Aiming to help people with diabetes to
have more personalised consultations with their HCPs, the device
will allow dose logging.
- Financial participation of Novo Nordisk in the development plan
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME),
a French company specialized in the design, development, and
manufacturing of innovative medical devices, today announces an
agreement with Novo Nordisk, a world leader in diabetes care, for
the development and distribution (pending successful development)
of a Mallya smart add-on device for the Novo Nordisk FlexTouch pen
used by people with diabetes.
Mallya is a Bluetooth enabled smart add-on device for pen
injectors that collects dose and time of each injection and
transfers information in real time to a companion software. Mallya
helps people with diabetes maintain a reliable dose log, using
technology to help improve understanding and allowing people to
dose with confidence.
Most Novo Nordisk's insulins are offered with the FlexTouch pen,
and it is part of the launch map for all new insulins. A specific
version of Mallya will be developed for FlexTouch, the first
prefilled insulin delivery device with no-push-button extension.
Due to the unique dosing mechanism of FlexTouch, the push button
does not extend at any dose and allows insulin to be administered
by pressing the low injection force button. The existing Mallya
device had to be redesigned to meet the needs of this mechanism,
keeping its accuracy and reliability for the patient.
Directly attached on the disposable pre-filled FlexTouch pen,
Mallya will allow seamless and efficient dose logging on FlexTouch,
which could help people with diabetes and their HCPs to have more
personalized conversations about the disease and treatment
Biocorp will receive an upfront payment and different milestones
are defined staging the development phase. Upon successful
development, Novo Nordisk plans to distribute the smart device in
selected countries, and Biocorp expects to ramp up production
volumes from 2022. Financials and terms of contract are not
“Novo Nordisk collaborates with Biocorp as we believe people
with diabetes deserve the freedom to decide which solution works
best for them. Our Swedish study1 demonstrates the health benefits
associated with the use of smart insulin pens. And as we continue
launching such smart pens, we also partner with Biocorp to allow
even more people with diabetes to reap the benefits connected
devices can provide. This collaboration demonstrates our commitment
to making diabetes management easier by giving people access to
data on medication usage behaviour which is known to potentially
result in improved patient outcomes”, said Søren Smed Østergaard,
vice president of Digital Health at Novo Nordisk.
“Biocorp is very proud to sign this partnership with the world's
leading diabetes company, Novo Nordisk, and it is a huge
recognition for our Mallya. Providing almost 50% of the insulin
used worldwide, Novo Nordisk distributed more than 500 million
insulin pens in 2020, treating close to 30 million patients. The
FlexTouch pen is not concerned by Mallya's current version, while
used by tens of millions of patients with diabetes in the world, so
we are pleased to be working to open up the possibilities of
connectivity for the many patients around the world who use this
pen.”, said Éric Dessertenne, CEO of BIOCORP.
Recognized for its expertise in the development and manufacture
of medical devices and delivery systems, BIOCORP has today acquired
a leading position in the connected medical device market thanks to
Mallya. This smart sensor for insulin injection pens allows
reliable monitoring of injected doses and thus offers better
compliance in the treatment of patients with diabetes. Available
for sale from 2020, Mallya spearheads BIOCORP's product portfolio
of innovative connected solutions. The company has 70 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 –
For more information, please visit www.biocorpsys.com.
1 “Increased Time in Range and Fewer Missed Bolus Injections
After Introduction of a Smart Connected Insulin Pen”, Diabetes
Technology & Therapeutics, Vol: 22(7), 2020.
version on businesswire.com: https://www.businesswire.com/news/home/20210926005031/en/
BIOCORP Sylvaine Dessard Senior Director Marketing &
Communication firstname.lastname@example.org + 33 (0)6 88 69 72 85
Bruno ARABIAN Press Officer email@example.com
+33 (0)6 87 88 46 26
Historical Stock Chart
Von Dez 2021 bis Jan 2022
Historical Stock Chart
Von Jan 2021 bis Jan 2022